Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation
jRCT1080222366Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant immunosuppression (2 arms), sponsored by Novartis. Started Jan 2014; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on jRCT1080222366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222366.